Entering text into the input field will update the search result below

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Jun. 29, 2022 9:02 AM ETPfizer Inc. (PFE) StockBy: SA News Team

Blood cells

Pixelimage/E+ via Getty Images

  • Global Blood Therapeutics (NASDAQ:GBT) said on Wednesday it had begun the Phase 2 portion of a Phase 2/3 trial of its drug candidate GBT601, to treat sickle cell disease.
  • The drug, GBT601, is a sickle hemoglobin (HbS) polymerization inhibitor and

Recommended For You

More Trending News

About PFE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PFE--
Pfizer Inc.